Targeted Delivery Methods for Anticancer Drugs
Abstract
:Simple Summary
Abstract
1. Introduction
2. Types of Containers and Carriers
2.1. Liposomes
- Physical adsorption onto the surface of liposomes.
- Covalent attachment using reactive groups on the surface of preformed liposomes.
- Inclusion of a PEG-lipid conjugate in liposome preparations.
2.2. Micelles
2.3. Solid-Lipid Nanoparticles
2.4. Gold Nanoparticles
2.5. Magnetic Nanoparticles
2.6. Dendrimers
2.7. Albumin-Based Nanoparticles
2.8. Porous Materials
2.9. Carbon Nanoparticles
2.10. Quantum Dots
2.11. Calcium Phosphate
2.12. Oligo- and Polysaccharide-Based Drug-Delivery Systems
2.12.1. Chitosan
2.12.2. Cyclodextrins
2.12.3. Pectins
3. The Targeting Methods of Delivery Systems
3.1. Antibodies and Aptamers
3.2. Proteins and Peptides
3.3. Low Molecular Weight Compounds
3.4. Small Molecule-Drug Conjugates
4. Stimuli-Responsive Drug Release
4.1. Enzyme-Sensitive Release
- The drug is conjugated to the delivery system with a linker cleaved by an enzyme that is overexpressed in the tumor environment.
- Enzyme cleavage sites are embedded into the envelope of the scaffolds, thereby destroying the envelope near or inside the tumor and releasing the encapsulated drug.
4.2. pH-Sensitive Release
4.3. Temperature-Sensitive Release
4.4. Other Stimuli
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Hanahan, D.; Weinberg, R.A. Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sonnenschein, C.; Soto, A.M. Over a century of cancer research: Inconvenient truths and promising leads. PLoS Biol. 2020, 18, e3000670. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Saraf, S.; Jain, A.; Tiwari, A.; Verma, A.; Panda, P.K.; Jain, S.K. Advances in liposomal drug delivery to cancer: An overview. J. Drug Deliv. Sci. Technol. 2020, 56, 101549. [Google Scholar] [CrossRef]
- Mandal, A.K. Dendrimers in targeted drug delivery applications: A review of diseases and cancer. Int. J. Polym. Mater. Polym. Biomater. 2021, 70, 287–297. [Google Scholar] [CrossRef]
- Siddique, S.; Chow, J.C.L. Gold Nanoparticles for Drug Delivery and Cancer Therapy. Appl. Sci. 2020, 10, 3824. [Google Scholar] [CrossRef]
- Farzin, A.; Etesami, S.A.; Quint, J.; Memic, A.; Tamayol, A. Magnetic Nanoparticles in Cancer Therapy and Diagnosis. Adv. Healthc. Mater. 2020, 9, 1901058. [Google Scholar] [CrossRef]
- Park, E.K.; Lee, S.B.; Lee, Y.M. Preparation and characterization of methoxy poly(ethylene glycol)/poly(ε-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials 2005, 26, 1053–1061. [Google Scholar] [CrossRef]
- Vinothini, K.; Rajendran, N.K.; Ramu, A.; Elumalai, N.; Rajan, M. Folate receptor targeted delivery of paclitaxel to breast cancer cells via folic acid conjugated graphene oxide grafted methyl acrylate nanocarrier. Biomed. Pharmacother. 2019, 110, 906–917. [Google Scholar] [CrossRef]
- Tagde, P.; Kulkarni, G.T.; Mishra, D.K.; Kesharwani, P. Recent advances in folic acid engineered nanocarriers for treatment of breast cancer. J. Drug Deliv. Sci. Technol. 2020, 56, 101613. [Google Scholar] [CrossRef]
- Zhang, Y.; Hong, H.; Cai, W. Tumor-Targeted Drug Delivery with Aptamers. Curr. Med. Chem. 2011, 18, 4185–4194. [Google Scholar] [CrossRef] [Green Version]
- Zununi Vahed, S.; Fathi, N.; Samiei, M.; Maleki Dizaj, S.; Sharifi, S. Targeted cancer drug delivery with aptamer-functionalized polymeric nanoparticles. J. Drug Target. 2019, 27, 292–299. [Google Scholar] [CrossRef] [PubMed]
- Farasat, A.; Rahbarizadeh, F.; Ahmadvand, D.; Ranjbar, S.; Khoshtinat Nikkhoi, S. Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin. J. Liposome Res. 2019, 29, 53–65. [Google Scholar] [CrossRef] [PubMed]
- Sheeba, C.J.; Marslin, G.; Revina, A.M.; Franklin, G. Signaling pathways influencing tumor microenvironment and their exploitation for targeted drug delivery. Nanotechnol. Rev. 2014, 3, 123–151. [Google Scholar] [CrossRef] [Green Version]
- Alvarez-Lorenzo, C.; Concheiro, A. Chapter 1. From Drug Dosage Forms to Intelligent Drug-delivery Systems: A Change of Paradigm. In Smart Materials for Drug Delivery; Alvarez-Lorenzo, C., Concheiro, A., Eds.; Smart Materials Series; Royal Society of Chemistry: Cambridge, UK, 2013; Volume 29, pp. 1–32. ISBN 978-1-84973-877-4. [Google Scholar]
- Kotzabasaki, M.; Froudakis, G.E. Review of computer simulations on anti-cancer drug delivery in MOFs. Inorg. Chem. Front. 2018, 5, 1255–1272. [Google Scholar] [CrossRef]
- Wang, Z.; Deng, X.; Ding, J.; Zhou, W.; Zheng, X.; Tang, G. Mechanisms of drug release in pH-sensitive micelles for tumour targeted drug delivery system: A review. Int. J. Pharm. 2018, 535, 253–260. [Google Scholar] [CrossRef]
- Hare, J.I.; Lammers, T.; Ashford, M.B.; Puri, S.; Storm, G.; Barry, S.T. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv. Drug Deliv. Rev. 2017, 108, 25–38. [Google Scholar] [CrossRef] [Green Version]
- Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs. Cancer Res. 1986, 46, 6387–6392. [Google Scholar]
- Park, J.; Choi, Y.; Chang, H.; Um, W.; Ryu, J.H.; Kwon, I.C. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment. Theranostics 2019, 9, 8073–8090. [Google Scholar] [CrossRef]
- Huang, D.; Sun, L.; Huang, L.; Chen, Y. Nanodrug Delivery Systems Modulate Tumor Vessels to Increase the Enhanced Permeability and Retention Effect. J. Pers. Med. 2021, 11, 124. [Google Scholar] [CrossRef]
- Fang, J.; Islam, W.; Maeda, H. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers. Adv. Drug Deliv. Rev. 2020, 157, 142–160. [Google Scholar] [CrossRef]
- Wu, J. The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. J. Pers. Med. 2021, 11, 771. [Google Scholar] [CrossRef] [PubMed]
- Shi, Y.; van der Meel, R.; Chen, X.; Lammers, T. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy. Theranostics 2020, 10, 7921–7924. [Google Scholar] [CrossRef] [PubMed]
- Danhier, F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J. Control. Release 2016, 244, 108–121. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Jiang, J.; Meng, H. Transcytosis—An effective targeting strategy that is complementary to “EPR effect” for pancreatic cancer nano drug delivery. Theranostics 2019, 9, 8018–8025. [Google Scholar] [CrossRef]
- Subhan, M.A.; Yalamarty, S.S.K.; Filipczak, N.; Parveen, F.; Torchilin, V.P. Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. J. Pers. Med. 2021, 11, 571. [Google Scholar] [CrossRef]
- Maherani, B.; Arab-Tehrany, E.; Mozafari, M.R.; Gaiani, C.; Linder, M. Liposomes: A Review of Manufacturing Techniques and Targeting Strategies. Curr. Nanosci. 2011, 7, 436–452. [Google Scholar] [CrossRef]
- Meure, L.A.; Foster, N.R.; Dehghani, F. Conventional and Dense Gas Techniques for the Production of Liposomes: A Review. AAPS PharmSciTech 2008, 9, 798. [Google Scholar] [CrossRef] [Green Version]
- Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4, 145–160. [Google Scholar] [CrossRef]
- Bangham, A.D.; Standish, M.M.; Watkins, J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 1965, 13, 238–252. [Google Scholar] [CrossRef]
- Zahednezhad, F.; Saadat, M.; Valizadeh, H.; Zakeri-Milani, P.; Baradaran, B. Liposome and immune system interplay: Challenges and potentials. J. Control. Release 2019, 305, 194–209. [Google Scholar] [CrossRef]
- Klibanov, A.L.; Maruyama, K.; Torchilin, V.P.; Huang, L. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268, 235–237. [Google Scholar] [CrossRef] [Green Version]
- Allen, C.; Dos Santos, N.; Gallagher, R.; Chiu, G.N.C.; Shu, Y.; Li, W.M.; Johnstone, S.A.; Janoff, A.S.; Mayer, L.D.; Webb, M.S.; et al. Controlling the Physical Behavior and Biological Performance of Liposome Formulations Through Use of Surface Grafted Poly(ethylene Glycol). Biosci. Rep. 2002, 22, 225–250. [Google Scholar] [CrossRef] [PubMed]
- Needham, D.; McIntosh, T.J.; Lasic, D.D. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim. Biophys. Acta Biomembr. 1992, 1108, 40–48. [Google Scholar] [CrossRef]
- Mahmood, I.; Green, M.D. Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins. Clin. Pharmacokinet. 2005, 44, 331–347. [Google Scholar] [CrossRef]
- Macdougall, I.C. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr. Hematol. Rep. 2005, 4, 436–440. [Google Scholar]
- Sercombe, L.; Veerati, T.; Moheimani, F.; Wu, S.Y.; Sood, A.K.; Hua, S. Advances and Challenges of Liposome Assisted Drug Delivery. Front. Pharmacol. 2015, 6, 286. [Google Scholar] [CrossRef] [Green Version]
- Torchilin, V.P. Micellar Nanocarriers: Pharmaceutical Perspectives. Pharm. Res. 2006, 24, 1–16. [Google Scholar] [CrossRef]
- Hassankhani Rad, A.; Asiaee, F.; Jafari, S.; Shayanfar, A.; Lavasanifar, A.; Molavi, O. Poly(ethylene glycol)-poly(ε-caprolactone)-based micelles for solubilization and tumor-targeted delivery of silibinin. BioImpacts 2019, 10, 87–95. [Google Scholar] [CrossRef] [Green Version]
- Biswas, S.; Kumari, P.; Lakhani, P.M.; Ghosh, B. Recent advances in polymeric micelles for anti-cancer drug delivery. Eur. J. Pharm. Sci. 2016, 83, 184–202. [Google Scholar] [CrossRef]
- Kwon, G.; Suwa, S.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Kataoka, K. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly (ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J. Control. Release 1994, 29, 17–23. [Google Scholar] [CrossRef]
- Hanafy, N.; El-Kemary, M.; Leporatti, S. Micelles Structure Development as a Strategy to Improve Smart Cancer Therapy. Cancers 2018, 10, 238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shi, M.; Sun, J.; Zhou, J.; Yu, H.; Yu, S.; Xia, G.; Wang, L.; Teng, Y.; Liu, G.; Yu, C.; et al. Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies. Investig. New Drugs 2018, 36, 269–277. [Google Scholar] [CrossRef] [PubMed]
- Onoue, S.; Yamada, S.; Chan, K. Nanodrugs: Pharmacokinetics and safety. Int. J. Nanomed. 2014, 9, 1025–1037. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, Q.; Cai, T.; Huang, Y.; Xia, X.; Cole, S.; Cai, Y. A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs. Nanomaterials 2017, 7, 122. [Google Scholar] [CrossRef] [PubMed]
- Wong, H.L.; Bendayan, R.; Rauth, A.M.; Li, Y.; Wu, X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2007, 59, 491–504. [Google Scholar] [CrossRef] [PubMed]
- Dreaden, E.C.; Mwakwari, S.C.; Sodji, Q.H.; Oyelere, A.K.; El-Sayed, M.A. Tamoxifen−Poly(ethylene glycol)−Thiol Gold Nanoparticle Conjugates: Enhanced Potency and Selective Delivery for Breast Cancer Treatment. Bioconjug. Chem. 2009, 20, 2247–2253. [Google Scholar] [CrossRef] [Green Version]
- Dhar, S.; Daniel, W.L.; Giljohann, D.A.; Mirkin, C.A.; Lippard, S.J. Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) Warheads. J. Am. Chem. Soc. 2009, 131, 14652–14653. [Google Scholar] [CrossRef]
- Mukherjee, P.; Bhattacharya, R.; Wang, P.; Wang, L.; Basu, S.; Nagy, J.A.; Atala, A.; Mukhopadhyay, D.; Soker, S. Antiangiogenic Properties of Gold Nanoparticles. Clin. Cancer Res. 2005, 11, 3530–3534. [Google Scholar] [CrossRef] [Green Version]
- Nel, A.E.; Mädler, L.; Velegol, D.; Xia, T.; Hoek, E.M.V.; Somasundaran, P.; Klaessig, F.; Castranova, V.; Thompson, M. Understanding biophysicochemical interactions at the nano–bio interface. Nat. Mater. 2009, 8, 543–557. [Google Scholar] [CrossRef]
- Khan, A.K.; Rashid, R.; Murtaza, G.; Zahra, A. Gold Nanoparticles: Synthesis and Applications in Drug Delivery. Trop. J. Pharm. Res. 2014, 13, 1169–1177. [Google Scholar] [CrossRef]
- Dreaden, E.C.; Austin, L.A.; Mackey, M.A.; El-Sayed, M.A. Size matters: Gold nanoparticles in targeted cancer drug delivery. Ther. Deliv. 2012, 3, 457–478. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manju, S.; Sreenivasan, K. Gold nanoparticles generated and stabilized by water soluble curcumin–polymer conjugate: Blood compatibility evaluation and targeted drug delivery onto cancer cells. J. Colloid Interface Sci. 2012, 368, 144–151. [Google Scholar] [CrossRef] [PubMed]
- Rahme, K.; Guo, J.; Holmes, J.D. Bioconjugated Gold Nanoparticles Enhance siRNA Delivery in Prostate Cancer Cells. In Methods in Molecular Biology; Humana: New York, NY, USA, 2019; Volume 1974, pp. 291–301. [Google Scholar]
- Wang, F.; Wang, Y.-C.; Dou, S.; Xiong, M.-H.; Sun, T.-M.; Wang, J. Doxorubicin-Tethered Responsive Gold Nanoparticles Facilitate Intracellular Drug Delivery for Overcoming Multidrug Resistance in Cancer Cells. ACS Nano 2011, 5, 3679–3692. [Google Scholar] [CrossRef]
- Asadishad, B.; Vossoughi, M.; Alemzadeh, I. Folate-receptor-targeted delivery of doxorubicin using polyethylene glycol-functionalized gold nanoparticles. Ind. Eng. Chem. Res. 2010, 49, 1958–1963. [Google Scholar] [CrossRef]
- Khodashenas, B.; Ardjmand, M.; Rad, A.S.; Esfahani, M.R. Gelatin-coated gold nanoparticles as an effective pH-sensitive methotrexate drug delivery system for breast cancer treatment. Mater. Today Chem. 2021, 20, 100474. [Google Scholar] [CrossRef]
- Yücel, O.; Şengelen, A.; Emik, S.; Önay-Uçar, E.; Arda, N.; Gürdağ, G. Folic acid-modified methotrexate-conjugated gold nanoparticles as nano-sized trojans for drug delivery to folate receptor-positive cancer cells. Nanotechnology 2020, 31, 355101. [Google Scholar] [CrossRef] [PubMed]
- Lim, E.K.; Huh, Y.M.; Yang, J.; Lee, K.; Suh, J.S.; Haam, S. PH-triggered drug-releasing magnetic nanoparticles for cancer therapy guided by molecular imaging by MRI. Adv. Mater. 2011, 23, 2436–2442. [Google Scholar] [CrossRef]
- Gupta, A.K.; Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26, 3995–4021. [Google Scholar] [CrossRef]
- Alromi, D.A.; Madani, S.Y.; Seifalian, A. Emerging Application of Magnetic Nanoparticles for Diagnosis and Treatment of Cancer. Polymers 2021, 13, 4146. [Google Scholar] [CrossRef]
- El-Boubbou, K. Magnetic iron oxide nanoparticles as drug carriers: Preparation, conjugation and delivery. Nanomedicine 2018, 13, 929–952. [Google Scholar] [CrossRef]
- Dan, M.; Bae, Y.; Pittman, T.A.; Yokel, R.A. Alternating Magnetic Field-Induced Hyperthermia Increases Iron Oxide Nanoparticle Cell Association/Uptake and Flux in Blood-Brain Barrier Models. Pharm. Res. 2015, 32, 1615–1625. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wallyn, J.; Anton, N.; Vandamme, T.F. Synthesis, Principles, and Properties of Magnetite Nanoparticles for In Vivo Imaging Applications—A Review. Pharmaceutics 2019, 11, 601. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tourinho, F.; Franck, R.; Massart, R.; Perzynski, R. Synthesis and mangeitc properties of managanese and cobalt ferrite ferrite ferrofluids. In Trends in Colloid and Interface Science III; Steinkopff: Darmstadt, Germany, 2007; pp. 128–134. [Google Scholar]
- Hosu, O.; Tertis, M.; Cristea, C. Implication of Magnetic Nanoparticles in Cancer Detection, Screening and Treatment. Magnetochemistry 2019, 5, 55. [Google Scholar] [CrossRef] [Green Version]
- Manescu (Paltanea), V.; Paltanea, G.; Antoniac, I.; Vasilescu, M. Magnetic Nanoparticles Used in Oncology. Materials 2021, 14, 5948. [Google Scholar] [CrossRef]
- Kim, D.K.; Zhang, Y.; Voit, W.; Rao, K.V.; Muhammed, M. Synthesis and characterization of surfactant-coated superparamagnetic monodispersed iron oxide nanoparticles. J. Magn. Magn. Mater. 2001, 225, 30–36. [Google Scholar] [CrossRef]
- Sun, C.; Du, K.; Fang, C.; Bhattarai, N.; Veiseh, O.; Kievit, F.; Stephen, Z.; Lee, D.; Ellenbogen, R.G.; Ratner, B.; et al. PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: Their physicochemical properties and function in vivo. ACS Nano 2010, 4, 2402–2410. [Google Scholar] [CrossRef] [Green Version]
- Gupta, A.K.; Wells, S. Surface-Modified Superparamagnetic Nanoparticles for Drug Delivery: Preparation, Characterization, and Cytotoxicity Studies. IEEE Trans. Nanobiosci. 2004, 3, 66–73. [Google Scholar] [CrossRef]
- Sharifianjazi, F.; Irani, M.; Esmaeilkhanian, A.; Bazli, L.; Asl, M.S.; Jang, H.W.; Kim, S.Y.; Ramakrishna, S.; Shokouhimehr, M.; Varma, R.S. Polymer incorporated magnetic nanoparticles: Applications for magnetoresponsive targeted drug delivery. Mater. Sci. Eng. B 2021, 272, 115358. [Google Scholar] [CrossRef]
- Nagesh, P.K.B.; Johnson, N.R.; Boya, V.K.N.; Chowdhury, P.; Othman, S.F.; Khalilzad-Sharghi, V.; Hafeez, B.B.; Ganju, A.; Khan, S.; Behrman, S.W.; et al. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. Colloids Surf. B Biointerfaces 2016, 144, 8–20. [Google Scholar] [CrossRef] [Green Version]
- Chandra, S.; Noronha, G.; Dietrich, S.; Lang, H.; Bahadur, D. Dendrimer-magnetic nanoparticles as multiple stimuli responsive and enzymatic drug delivery vehicle. J. Magn. Magn. Mater. 2015, 380, 7–12. [Google Scholar] [CrossRef]
- Bhattacharya, D.; Behera, B.; Sahu, S.K.; Ananthakrishnan, R.; Maiti, T.K.; Pramanik, P. Design of dual stimuli responsive polymer modified magnetic nanoparticles for targeted anti-cancer drug delivery and enhanced MR imaging. New J. Chem. 2016, 40, 545–557. [Google Scholar] [CrossRef]
- Roy, E.; Patra, S.; Madhuri, R.; Sharma, P.K. Stimuli-responsive poly(N-isopropyl acrylamide)-co-tyrosine@gadolinium: Iron oxide nanoparticle-based nanotheranostic for cancer diagnosis and treatment. Colloids Surf. B Biointerfaces 2016, 142, 248–258. [Google Scholar] [CrossRef] [PubMed]
- Zohreh, N.; Hosseini, S.H.; Pourjavadi, A. Hydrazine-modified starch coated magnetic nanoparticles as an effective pH-responsive nanocarrier for doxorubicin delivery. J. Ind. Eng. Chem. 2016, 39, 203–209. [Google Scholar] [CrossRef] [Green Version]
- Mangaiyarkarasi, R.; Chinnathambi, S.; Karthikeyan, S.; Aruna, P.; Ganesan, S. Paclitaxel conjugated Fe3O4@LaF3:Ce3+,Tb3+ nanoparticles as bifunctional targeting carriers for Cancer theranostics application. J. Magn. Magn. Mater. 2016, 399, 207–215. [Google Scholar] [CrossRef]
- Chen, H.; Sulejmanovic, D.; Moore, T.; Colvin, D.C.; Qi, B.; Mefford, O.T.; Gore, J.C.; Alexis, F.; Hwu, S.-J.; Anker, J.N. Iron-Loaded Magnetic Nanocapsules for pH-Triggered Drug Release and MRI Imaging. Chem. Mater. 2014, 26, 2105–2112. [Google Scholar] [CrossRef]
- Hovhannisyan, V.; Siposova, K.; Musatov, A.; Chen, S.J. Development of multifunctional nanocomposites for controlled drug delivery and hyperthermia. Sci. Rep. 2021, 11, 5528. [Google Scholar] [CrossRef]
- Hepel, M. Magnetic Nanoparticles for Nanomedicine. Magnetochemistry 2020, 6, 3. [Google Scholar] [CrossRef] [Green Version]
- Gillies, E.R.; Fréchet, J.M.J. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 2005, 10, 35–43. [Google Scholar] [CrossRef]
- Gupta, U.; Dwivedi, S.K.D.; Bid, H.K.; Konwar, R.; Jain, N.K. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int. J. Pharm. 2010, 393, 186–197. [Google Scholar] [CrossRef]
- Chan, W.C.W. Nanomedicine 2.0. Acc. Chem. Res. 2017, 50, 627–632. [Google Scholar] [CrossRef]
- She, W.; Pan, D.; Luo, K.; He, B.; Cheng, G.; Zhang, C.; Gu, Z. PEGylated dendrimer-doxorubicin cojugates as pH-sensitive drug delivery systems: Synthesis and in vitro characterization. J. Biomed. Nanotechnol. 2015, 11, 964–978. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Froehling, P.E. Dendrimers and dyes—A review. Dye Pigment. 2001, 48, 187–195. [Google Scholar] [CrossRef]
- Holister, P.; Vas, C.R.; Harper, T. Dendrimers, Technology White Papers nr.6; Cientifica: London, UK, 2003. [Google Scholar]
- Abedi-Gaballu, F.; Dehghan, G.; Ghaffari, M.; Yekta, R.; Abbaspour-Ravasjani, S.; Baradaran, B.; Ezzati Nazhad Dolatabadi, J.; Hamblin, M.R. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl. Mater. Today 2018, 12, 177–190. [Google Scholar] [CrossRef] [PubMed]
- Ambekar, R.S.; Choudhary, M.; Kandasubramanian, B. Recent advances in dendrimer-based nanoplatform for cancer treatment: A review. Eur. Polym. J. 2020, 126, 109546. [Google Scholar] [CrossRef]
- Majoros, I.J.; Myc, A.; Thomas, T.; Mehta, C.B.; Baker, J.R. PAMAM Dendrimer-Based Multifunctional Conjugate for Cancer Therapy: Synthesis, Characterization, and Functionality. Biomacromolecules 2006, 7, 572–579. [Google Scholar] [CrossRef]
- Singh, V.; Sahebkar, A.; Kesharwani, P. Poly (propylene imine) dendrimer as an emerging polymeric nanocarrier for anticancer drug and gene delivery. Eur. Polym. J. 2021, 158, 110683. [Google Scholar] [CrossRef]
- Gorzkiewicz, M.; Kopeć, O.; Janaszewska, A.; Konopka, M.; Pędziwiatr-Werbicka, E.; Tarasenko, I.I.; Bezrodnyi, V.V.; Neelov, I.M.; Klajnert-Maculewicz, B. Poly(lysine) Dendrimers Form Complexes with siRNA and Provide Its Efficient Uptake by Myeloid Cells: Model Studies for Therapeutic Nucleic Acid Delivery. Int. J. Mol. Sci. 2020, 21, 3138. [Google Scholar] [CrossRef]
- Ambrosio, L.; Argenziano, M.; Cucci, M.A.; Grattarola, M.; de Graaf, I.A.M.; Dianzani, C.; Barrera, G.; Sánchez Nieves, J.; Gomez, R.; Cavalli, R.; et al. Carbosilane Dendrimers Loaded with siRNA Targeting Nrf2 as a Tool to Overcome Cisplatin Chemoresistance in Bladder Cancer Cells. Antioxidants 2020, 9, 993. [Google Scholar] [CrossRef]
- Chen, L.; Li, J.; Fan, Y.; Qiu, J.; Cao, L.; Laurent, R.; Mignani, S.; Caminade, A.-M.; Majoral, J.-P.; Shi, X. Revisiting Cationic Phosphorus Dendrimers as a Nonviral Vector for Optimized Gene Delivery Toward Cancer Therapy Applications. Biomacromolecules 2020, 21, 2502–2511. [Google Scholar] [CrossRef]
- Jain, N.K.; Tare, M.S.; Mishra, V.; Tripathi, P.K. The development, characterization and in vivo anti-ovarian cancer activity of poly(propylene imine) (PPI)-antibody conjugates containing encapsulated paclitaxel. Nanomed. Nanotechnol. Biol. Med. 2015, 11, 207–218. [Google Scholar] [CrossRef]
- Van Dongen, M.A.; Rattan, R.; Silpe, J.; Dougherty, C.; Michmerhuizen, N.L.; Van Winkle, M.; Huang, B.; Choi, S.K.; Sinniah, K.; Orr, B.G.; et al. Poly(amidoamine) Dendrimer-Methotrexate Conjugates: The Mechanism of Interaction with Folate Binding Protein. Mol. Pharm. 2014, 11, 4049–4058. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Al-Jamal, K.T.; Al-Jamal, W.T.; Wang, J.T.W.; Rubio, N.; Buddle, J.; Gathercole, D.; Zloh, M.; Kostarelos, K. Cationic poly-L-Lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo. ACS Nano 2013, 7, 1905–1917. [Google Scholar] [CrossRef] [PubMed]
- Poupot, M.; Turrin, C.O.; Caminade, A.M.; Fournié, J.J.; Attal, M.; Poupot, R.; Fruchon, S. Poly(phosphorhydrazone) dendrimers: Yin and yang of monocyte activation for human NK cell amplification applied to immunotherapy against multiple myeloma. Nanomed. Nanotechnol. Biol. Med. 2016, 12, 2321–2330. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Liang, H.; Liu, J.; Wang, Z. Poly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy. Int. J. Pharm. 2018, 546, 215–225. [Google Scholar] [CrossRef] [PubMed]
- Dhumal, D.; Lan, W.; Ding, L.; Jiang, Y.; Lyu, Z.; Laurini, E.; Marson, D.; Tintaru, A.; Dusetti, N.; Giorgio, S.; et al. An ionizable supramolecular dendrimer nanosystem for effective siRNA delivery with a favorable safety profile. Nano Res. 2021, 14, 2247–2254. [Google Scholar] [CrossRef]
- Dias, A.P.; da Silva Santos, S.; da Silva, J.V.; Parise-Filho, R.; Igne Ferreira, E.; Seoud, O.E.; Giarolla, J. Dendrimers in the context of nanomedicine. Int. J. Pharm. 2020, 573, 118814. [Google Scholar] [CrossRef]
- Parodi, A.; Miao, J.; Soond, S.M.; Rudzińska, M.; Zamyatnin, A.A. Albumin nanovectors in cancer therapy and imaging. Biomolecules 2019, 9, 218. [Google Scholar] [CrossRef] [Green Version]
- Elzoghby, A.O.; Samy, W.M.; Elgindy, N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release 2012, 157, 168–182. [Google Scholar] [CrossRef]
- Krach-Hansen, U.; Chuang, V.T.G.; Otagiri, M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 2002, 25, 695–704. [Google Scholar] [CrossRef] [Green Version]
- Yang, F.; Zhang, Y.; Liang, H. Interactive Association of Drugs Binding to Human Serum Albumin. Int. J. Mol. Sci. 2014, 15, 3580–3595. [Google Scholar] [CrossRef]
- Kratz, F.; Warnecke, A.; Scheuermann, K.; Stockmar, C.; Rgen Schwab, J.; Lazar, P.; Drü, P.; Esser, N.; Drevs, J.; Rognan, D.; et al. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin. J. Med. Chem. 2002, 45, 5523–5533. [Google Scholar] [CrossRef] [PubMed]
- Larsen, M.T.; Kuhlmann, M.; Hvam, M.L.; Howard, K.A. Albumin-based drug delivery: Harnessing nature to cure disease. Mol. Cell. Ther. 2016, 4, 3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- An, F.-F.; Zhang, X.-H. Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery. Theranostics 2017, 7, 3667–3689. [Google Scholar] [CrossRef] [PubMed]
- Van de Sande, L.; Cosyns, S.; Willaert, W.; Ceelen, W. Albumin-based cancer therapeutics for intraperitoneal drug delivery: A review. Drug Deliv. 2020, 27, 40–53. [Google Scholar] [CrossRef]
- Hoogenboezem, E.N.; Duvall, C.L. Harnessing albumin as a carrier for cancer therapies. Adv. Drug Deliv. Rev. 2018, 130, 73–89. [Google Scholar] [CrossRef]
- Solanki, R.; Rostamabadi, H.; Patel, S.; Jafari, S.M. Anticancer nano-delivery systems based on bovine serum albumin nanoparticles: A critical review. Int. J. Biol. Macromol. 2021, 193, 528–540. [Google Scholar] [CrossRef]
- Fu, Q.; Sun, J.; Zhang, W.; Sui, X.; Yan, Z.; He, Z. Nanoparticle Albumin-Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery. Recent Pat. Anticancer Drug Discov. 2009, 4, 262–272. [Google Scholar] [CrossRef]
- Kianfar, E. Protein nanoparticles in drug delivery: Animal protein, plant proteins and protein cages, albumin nanoparticles. J. Nanobiotechnol. 2021, 19, 159. [Google Scholar] [CrossRef]
- Cortes, J.; Saura, C. Nanoparticle albumin-bound (nabTM)-paclitaxel: Improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer. Eur. J. Cancer Suppl. 2010, 8, 1–10. [Google Scholar] [CrossRef]
- Unger, C.; Häring, B.; Medinger, M.; Drevs, J.; Steinbild, S.; Kratz, F.; Mross, K. Phase I and pharmacokinetic study of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin. Clin. Cancer Res. 2007, 13, 4858–4866. [Google Scholar] [CrossRef] [Green Version]
- Saleh, T.; Soudi, T.; Shojaosadati, S.A. Aptamer functionalized curcumin-loaded human serum albumin (HSA) nanoparticles for targeted delivery to HER-2 positive breast cancer cells. Int. J. Biol. Macromol. 2019, 130, 109–116. [Google Scholar] [CrossRef] [PubMed]
- Prajapati, R.; Garcia-Garrido, E.; Somoza, Á. Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer. Cancers 2021, 13, 3011. [Google Scholar] [CrossRef] [PubMed]
- Mizuta, Y.; Maeda, H.; Ishima, Y.; Minayoshi, Y.; Ichimizu, S.; Kinoshita, R.; Fujita, I.; Kai, T.; Hirata, K.; Nakamura, T.; et al. A Mannosylated, PEGylated Albumin as a Drug Delivery System for the Treatment of Cancer Stroma Cells. Adv. Funct. Mater. 2021, 31, 2104136. [Google Scholar] [CrossRef]
- Wang, D.; Li, H.; Chen, W.; Yang, H.; Liu, Y.; You, B.; Zhang, X. Efficient tumor-targeting delivery of siRNA via folate-receptor mediated biomimetic albumin nanoparticles enhanced by all-trans retinoic acid. Mater. Sci. Eng. C 2021, 119, 111583. [Google Scholar] [CrossRef]
- Kraljević Pavelić, S.; Simović Medica, J.; Gumbarević, D.; Filošević, A.; Pržulj, N.; Pavelić, K. Critical Review on Zeolite Clinoptilolite Safety and Medical Applications in vivo. Front. Pharmacol. 2018, 9, 1350. [Google Scholar] [CrossRef]
- Serati-Nouri, H.; Jafari, A.; Roshangar, L.; Dadashpour, M.; Pilehvar-Soltanahmadi, Y.; Zarghami, N. Biomedical applications of zeolite-based materials: A review. Mater. Sci. Eng. C 2020, 116, 111225. [Google Scholar] [CrossRef]
- Horcajada, P.; Rámila, A.; Pérez-Pariente, J.; Vallet-Regí, M. Influence of pore size of MCM-41 matrices on drug delivery rate. Microporous Mesoporous Mater. 2004, 68, 105–109. [Google Scholar] [CrossRef]
- Vilaça, N.; Bertão, A.R.; Prasetyanto, E.A.; Granja, S.; Costa, M.; Fernandes, R.; Figueiredo, F.; Fonseca, A.M.; De Cola, L.; Baltazar, F.; et al. Surface functionalization of zeolite-based drug delivery systems enhances their antitumoral activity in vivo. Mater. Sci. Eng. C 2021, 120, 111721. [Google Scholar] [CrossRef]
- Hao, J.; Stavljenić Milašin, I.; Batu Eken, Z.; Mravak-Stipetic, M.; Pavelić, K.; Ozer, F. Effects of Zeolite as a Drug Delivery System on Cancer Therapy: A Systematic Review. Molecules 2021, 26, 6196. [Google Scholar] [CrossRef]
- Vilaça, N.; Machado, A.F.; Morais-Santos, F.; Amorim, R.; Patrícia Neto, A.; Logodin, E.; Pereira, M.F.R.; Sardo, M.; Rocha, J.; Parpot, P.; et al. Comparison of different silica microporous structures as drug delivery systems for in vitro models of solid tumors. RSC Adv. 2017, 7, 13104–13111. [Google Scholar] [CrossRef] [Green Version]
- Ahali Abadeh, Z.; Saviano, G.; Ballirano, P.; Santonicola, M.G. Curcumin-loaded zeolite as anticancer drug carrier: Effect of curcumin adsorption on zeolite structure. Pure Appl. Chem. 2020, 92, 461–471. [Google Scholar] [CrossRef] [Green Version]
- Abd-Elsatar, A.G.; Farag, M.M.; Youssef, H.F.; Salih, S.A.; Mounier, M.M.; El-Meliegy, E. Different zeolite systems for colon cancer therapy: Monitoring of ion release, cytotoxicity and drug release behavior. Prog. Biomater. 2019, 8, 101–113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cao, X.-X.; Liu, S.-L.; Lu, J.-S.; Zhang, Z.-W.; Wang, G.; Chen, Q.; Lin, N. Chitosan coated biocompatible zeolitic imidazolate framework ZIF-90 for targeted delivery of anticancer drug methotrexate. J. Solid State Chem. 2021, 300, 122259. [Google Scholar] [CrossRef]
- Iturrioz-Rodríguez, N.; Correa-Duarte, M.A.; Fanarraga, M.L. Controlled drug delivery systems for cancer based on mesoporous silica nanoparticles. Int. J. Nanomed. 2019, 14, 3389–3401. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Khosraviyan, P.; Shafiee Ardestani, M.; Khoobi, M.; Ostad, S.N.; Dorkoosh, F.A.; Akbari Javar, H.; Amanlou, M. Mesoporous silica nanoparticles functionalized with folic acid/methionine for active targeted delivery of docetaxel. OncoTargets Ther. 2016, 9, 7315–7330. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kotcherlakota, R.; Barui, A.K.; Prashar, S.; Fajardo, M.; Briones, D.; Rodríguez-Diéguez, A.; Patra, C.R.; Gómez-Ruiz, S. Curcumin loaded mesoporous silica: An effective drug delivery system for cancer treatment. Biomater. Sci. 2016, 4, 448–459. [Google Scholar] [CrossRef] [PubMed]
- Meng, H.; Wang, M.; Liu, H.; Liu, X.; Situ, A.; Wu, B.; Ji, Z.; Chang, C.H.; Nel, A.E. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gmcitabine and pclitaxel dlivery to hman pncreatic cncer in mice. ACS Nano 2015, 9, 3540–3557. [Google Scholar] [CrossRef] [Green Version]
- Yang, Y.; Yu, C. Advances in silica based nanoparticles for targeted cancer therapy. Nanomed. Nanotechnol. Biol. Med. 2016, 12, 317–332. [Google Scholar] [CrossRef]
- Tang, F.; Li, L.; Chen, D. Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. Adv. Mater. 2012, 24, 1504–1534. [Google Scholar] [CrossRef]
- Wu, S.H.; Lin, H.P. Synthesis of mesoporous silica nanoparticles. Chem. Soc. Rev. 2013, 42, 3862–3875. [Google Scholar] [CrossRef]
- Paredes, K.O.; Díaz-García, D.; García-Almodóvar, V.; Chamizo, L.L.; Marciello, M.; Díaz-Sánchez, M.; Prashar, S.; Gómez-Ruiz, S.; Filice, M. Multifunctional silica-based nanoparticles with controlled release of organotin metallodrug for targeted theranosis of breast cancer. Cancers 2020, 12, 187. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, M.; Hu, J.; Wang, L.; Li, Y.; Zhu, C.; Chen, C.; Shi, M.; Ju, Z.; Cao, X.; Zhang, Z. Targeted and redox-responsive drug delivery systems based on carbonic anhydrase IX-decorated mesoporous silica nanoparticles for cancer therapy. Sci. Rep. 2020, 10, 14447. [Google Scholar] [CrossRef]
- Shakeran, Z.; Keyhanfar, M.; Varshosaz, J.; Sutherland, D.S. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment. Mater. Sci. Eng. C 2021, 118, 111526. [Google Scholar] [CrossRef] [PubMed]
- Lisik, K.; Krokosz, A. Application of Carbon Nanoparticles in Oncology and Regenerative Medicine. Int. J. Mol. Sci. 2021, 22, 8341. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Meng, L.; Lu, Q.; Fei, Z.; Dyson, P.J. Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials 2009, 30, 6041–6047. [Google Scholar] [CrossRef] [PubMed]
- Reineck, P.; Lau, D.W.M.; Wilson, E.R.; Fox, K.; Field, M.R.; Deeleepojananan, C.; Mochalin, V.N.; Gibson, B.C. Effect of Surface Chemistry on the Fluorescence of Detonation Nanodiamonds. ACS Nano 2017, 11, 10924–10934. [Google Scholar] [CrossRef] [PubMed]
- Heister, E.; Neves, V.; Tîlmaciu, C.; Lipert, K.; Beltrán, V.S.; Coley, H.M.; Silva, S.R.P.; McFadden, J. Triple functionalisation of single-walled carbon nanotubes with doxorubicin, a monoclonal antibody, and a fluorescent marker for targeted cancer therapy. Carbon 2009, 47, 2152–2160. [Google Scholar] [CrossRef] [Green Version]
- Guo, H.; Hu, H.; Yu, X.; Naito, K.; Zhang, Q. Covalent Functionalization of Nanodiamonds with Natural Amino Acids and Ascorbic Acids. J. Nanosci. Nanotechnol. 2019, 19, 7574–7583. [Google Scholar] [CrossRef]
- Raza, K.; Thotakura, N.; Kumar, P.; Joshi, M.; Bhushan, S.; Bhatia, A.; Kumar, V.; Malik, R.; Sharma, G.; Guru, S.K.; et al. C60-fullerenes for delivery of docetaxel to breast cancer cells: A promising approach for enhanced efficacy and better pharmacokinetic profile. Int. J. Pharm. 2015, 495, 551–559. [Google Scholar] [CrossRef]
- Kaur, J.; Gill, G.S.; Jeet, K. Applications of Carbon Nanotubes in Drug Delivery. In Characterization and Biology of Nanomaterials for Drug Delivery; Elsevier: Amsterdam, The Netherlands, 2019; pp. 113–135. ISBN 9780128140321. [Google Scholar]
- Youssef, Z.; Vanderesse, R.; Colombeau, L.; Baros, F.; Roques-Carmes, T.; Frochot, C.; Wahab, H.; Toufaily, J.; Hamieh, T.; Acherar, S.; et al. The application of titanium dioxide, zinc oxide, fullerene, and graphene nanoparticles in photodynamic therapy. Cancer Nanotechnol. 2017, 8, 6. [Google Scholar] [CrossRef]
- Uthappa, U.T.; Arvind, O.R.; Sriram, G.; Losic, D.; Ho-Young-Jung; Kigga, M.; Kurkuri, M.D. Nanodiamonds and their surface modification strategies for drug delivery applications. J. Drug Deliv. Sci. Technol. 2020, 60, 101993. [Google Scholar] [CrossRef]
- Lacerda, L.; Bianco, A.; Prato, M.; Kostarelos, K. Carbon nanotubes as nanomedicines: From toxicology to pharmacology. Adv. Drug Deliv. Rev. 2006, 58, 1460–1470. [Google Scholar] [CrossRef] [PubMed]
- Visalli, G.; Currò, M.; Iannazzo, D.; Pistone, A.; Pruiti Ciarello, M.; Acri, G.; Testagrossa, B.; Bertuccio, M.P.; Squeri, R.; Di Pietro, A. In vitro assessment of neurotoxicity and neuroinflammation of homemade MWCNTs. Environ. Toxicol. Pharmacol. 2017, 56, 121–128. [Google Scholar] [CrossRef] [PubMed]
- Lazzarino, G.; Fresta, C.G.; Chakraborty, A.; Wijesinghe, M.B.; Amorini, A.M.; Lazzarino, G.; Tavazzi, B.; Lunte, S.M.; Caraci, F.; Dhar, P.; et al. Non-toxic engineered carbon nanodiamond concentrations induce oxidative/nitrosative stress, imbalance of energy metabolism, and mitochondrial dysfunction in microglial and alveolar basal epithelial cells article. Cell Death Dis. 2018, 9, 245. [Google Scholar] [CrossRef]
- Naota, M.; Shimada, A.; Morita, T.; Inoue, K.; Takano, H. Translocation pathway of the intratracheally instilled C60 fullerene from the lung into the blood circulation in the mouse: Possible association of diffusion and caveolae-mediated pinocytosis. Toxicol. Pathol. 2009, 37, 456–462. [Google Scholar] [CrossRef] [Green Version]
- Chernova, T.; Murphy, F.A.; Galavotti, S.; Sun, X.M.; Powley, I.R.; Grosso, S.; Schinwald, A.; Zacarias-Cabeza, J.; Dudek, K.M.; Dinsdale, D.; et al. Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf). Curr. Biol. 2017, 27, 3302–3314.e6. [Google Scholar] [CrossRef] [Green Version]
- Kulkarni, N.S.; Guererro, Y.; Gupta, N.; Muth, A.; Gupta, V. Exploring potential of quantum dots as dual modality for cancer therapy and diagnosis. J. Drug Deliv. Sci. Technol. 2019, 49, 352–364. [Google Scholar] [CrossRef]
- Singh, M.A.; Rana, S.; Singh Sidhu, Y.; Kaur, K.; Kaur, K.; Sandhu, N.K.; Singh, A.; Singh, G.; Narang, R.K. Advances in combination of quantum dots and nanotechnology-based carrier systems against cancer-A critical review. Int. J. Bio-Pharma Res. 2019, 8, 2814–2825. [Google Scholar] [CrossRef]
- Molaei, M.J. Carbon quantum dots and their biomedical and therapeutic applications: A review. RSC Adv. 2019, 9, 6460–6481. [Google Scholar] [CrossRef]
- Khaledian, S.; Nalaini, F.; Mehrbakhsh, M.; Abdoli, M.; Salehi Zahabi, S. Applications of novel quantum dots derived from layered materials in cancer cell imaging. FlatChem 2021, 27, 100246. [Google Scholar] [CrossRef]
- Aladesuyi, O.A.; Oluwafemi, O.S. Synthesis strategies and application of ternary quantum dots—In cancer therapy. Nano-Struct. Nano-Objects 2020, 24, 100568. [Google Scholar] [CrossRef]
- Abdelhamid, H.N.; El-Bery, H.M.; Metwally, A.A.; Elshazly, M.; Hathout, R.M. Synthesis of CdS-modified chitosan quantum dots for the drug delivery of Sesamol. Carbohydr. Polym. 2019, 214, 90–99. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Huy, B.T.; Sakthivel, K.; Choi, H.J.; Joo, W.H.; Shin, S.K.; Lee, M.J.; Lee, Y.I. Highly fluorescent CdTe quantum dots with reduced cytotoxicity-A Robust biomarker. Sens. Bio-Sens. Res. 2015, 3, 46–52. [Google Scholar] [CrossRef] [Green Version]
- Yang, J.; Yao, M.H.; Wen, L.; Song, J.T.; Zhang, M.Z.; Zhao, Y.D.; Liu, B. Multifunctional quantum dot-polypeptide hybrid nanogel for targeted imaging and drug delivery. Nanoscale 2014, 6, 11282–11292. [Google Scholar] [CrossRef] [PubMed]
- Couvreur, P.; Grislain, L.; Lenaerts, V.; Brasseur, F.; Guiot, P.; Biernacki, A. Biodegradable Polymeric Nanoparticles as Drug Carrier for Antitumor Agents. In Polymeric Nanoparticles and Microspheres; CRC Press: Boca Raton, FL, USA, 2018; pp. 27–94. [Google Scholar]
- Alaghmandfard, A.; Sedighi, O.; Tabatabaei Rezaei, N.; Abedini, A.A.; Malek Khachatourian, A.; Toprak, M.S.; Seifalian, A. Recent advances in the modification of carbon-based quantum dots for biomedical applications. Mater. Sci. Eng. C 2021, 120, 111756. [Google Scholar] [CrossRef]
- Molaei, M.J. A review on nanostructured carbon quantum dots and their applications in biotechnology, sensors, and chemiluminescence. Talanta 2019, 196, 456–478. [Google Scholar] [CrossRef]
- Wang, X.; Sun, X.; Lao, J.; He, H.; Cheng, T.; Wang, M.; Wang, S.; Huang, F. Multifunctional graphene quantum dots for simultaneous targeted cellular imaging and drug delivery. Colloids Surf. B Biointerfaces 2014, 122, 638–644. [Google Scholar] [CrossRef]
- Ding, H.; Du, F.; Liu, P.; Chen, Z.; Shen, J. DNA-carbon dots function as fluorescent vehicles for drug delivery. ACS Appl. Mater. Interfaces 2015, 7, 6889–6897. [Google Scholar] [CrossRef]
- Han, C.; Zhang, X.; Wang, F.; Yu, Q.; Chen, F.; Shen, D.; Yang, Z.; Wang, T.; Jiang, M.; Deng, T.; et al. Duplex metal co-doped carbon quantum dots-based drug delivery system with intelligent adjustable size as adjuvant for synergistic cancer therapy. Carbon 2021, 183, 789–808. [Google Scholar] [CrossRef]
- Iannazzo, D.; Pistone, A.; Celesti, C.; Triolo, C.; Patané, S.; Giofré, S.V.; Romeo, R.; Ziccarelli, I.; Mancuso, R.; Gabriele, B.; et al. A smart nanovector for cancer targeted drug delivery based on graphene quantum dots. Nanomaterials 2019, 9, 282. [Google Scholar] [CrossRef] [Green Version]
- Khalifehzadeh, R.; Arami, H. Biodegradable calcium phosphate nanoparticles for cancer therapy. Adv. Colloid Interface Sci. 2020, 279, 102157. [Google Scholar] [CrossRef] [PubMed]
- Degli Esposti, L.; Carella, F.; Adamiano, A.; Tampieri, A.; Iafisco, M. Calcium phosphate-based nanosystems for advanced targeted nanomedicine. Drug Dev. Ind. Pharm. 2018, 44, 1223–1238. [Google Scholar] [CrossRef] [PubMed]
- Zhao, J.; Chen, G.; Pang, X.; Zhang, P.; Hou, X.; Chen, P.; Xie, Y.-W.; He, C.-Y.; Wang, Z.; Chen, Z.-Y. Calcium phosphate nanoneedle based gene delivery system for cancer genetic immunotherapy. Biomaterials 2020, 250, 120072. [Google Scholar] [CrossRef] [PubMed]
- Rodríguez-Ruiz, I.; Delgado-López, J.M.; Durán-Olivencia, M.A.; Iafisco, M.; Tampieri, A.; Colangelo, D.; Prat, M.; Gómez-Morales, J. pH-Responsive Delivery of Doxorubicin from Citrate–Apatite Nanocrystals with Tailored Carbonate Content. Langmuir 2013, 29, 8213–8221. [Google Scholar] [CrossRef] [PubMed]
- Tang, J.; Howard, C.B.; Mahler, S.M.; Thurecht, K.J.; Huang, L.; Xu, Z.P. Enhanced delivery of siRNA to triple negative breast cancer cells in vitro and in vivo through functionalizing lipid-coated calcium phosphate nanoparticles with dual target ligands. Nanoscale 2018, 10, 4258–4266. [Google Scholar] [CrossRef]
- Huang, J.-L.; Chen, H.-Z.; Gao, X.-L. Lipid-coated calcium phosphate nanoparticle and beyond: A versatile platform for drug delivery. J. Drug Target. 2018, 26, 398–406. [Google Scholar] [CrossRef]
- Iafisco, M.; Palazzo, B.; Martra, G.; Margiotta, N.; Piccinonna, S.; Natile, G.; Gandin, V.; Marzano, C.; Roveri, N. Nanocrystalline carbonate-apatites: Role of Ca/P ratio on the upload and release of anticancer platinum bisphosphonates. Nanoscale 2012, 4, 206–217. [Google Scholar] [CrossRef]
- Shubhra, Q.T.H.; Oyane, A.; Araki, H.; Nakamura, M.; Tsurushima, H. Calcium phosphate nanoparticles prepared from infusion fluids for stem cell transfection: Process optimization and cytotoxicity analysis. Biomater. Sci. 2017, 5, 972–981. [Google Scholar] [CrossRef]
- Cai, A.; Zhu, Y.; Qi, C. Biodegradable Inorganic Nanostructured Biomaterials for Drug Delivery. Adv. Mater. Interfaces 2020, 7, 2000819. [Google Scholar] [CrossRef]
- Sedelnikova, M.B.; Komarova, E.G.; Sharkeev, Y.P.; Chebodaeva, V.V.; Tolkacheva, T.V.; Kondranova, A.M.; Zakharenko, A.M.; Bakina, O. V Effect of the Porosity, Roughness, Wettability, and Charge of Micro-Arc Coatings on the Efficiency of Doxorubicin Delivery and Suppression of Cancer Cells. Coatings 2020, 10, 664. [Google Scholar] [CrossRef]
- Sun, Y.; Chen, Y.; Ma, X.; Yuan, Y.; Liu, C.; Kohn, J.; Qian, J. Mitochondria-Targeted Hydroxyapatite Nanoparticles for Selective Growth Inhibition of Lung Cancer in Vitro and in Vivo. ACS Appl. Mater. Interfaces 2016, 8, 25680–25690. [Google Scholar] [CrossRef] [PubMed]
- Ansari, L.; Derakhshi, M.; Bagheri, E.; Shahtahmassebi, N.; Malaekeh-Nikouei, B. Folate conjugation improved uptake and targeting of porous hydroxyapatite nanoparticles containing epirubicin to cancer cells. Pharm. Dev. Technol. 2020, 25, 601–609. [Google Scholar] [CrossRef] [PubMed]
- Huang, H.; Du, M.; Chen, J.; Zhong, S.; Wang, J. Preparation and characterization of abalone shells derived biological mesoporous hydroxyapatite microspheres for drug delivery. Mater. Sci. Eng. C 2020, 113, 110969. [Google Scholar] [CrossRef] [PubMed]
- Ram Prasad, S.; Jayakrishnan, A.; Sampath Kumar, T.S. Hydroxyapatite-poly(vinyl alcohol) core-shell nanoparticles for dual delivery of methotrexate and gemcitabine for bone cancer treatment. J. Drug Deliv. Sci. Technol. 2019, 51, 629–638. [Google Scholar] [CrossRef]
- Lee, S.; Miyajima, T.; Sugawara-Narutaki, A.; Kato, K.; Nagata, F. Development of paclitaxel-loaded poly(lactic acid)/hydroxyapatite core–shell nanoparticles as a stimuli-responsive drug delivery system. R. Soc. Open Sci. 2021, 8, 202030. [Google Scholar] [CrossRef]
- Li, S.; Zhang, L.; Zhang, H.; Mu, Z.; Li, L.; Wang, C. Rationally Designed Calcium Phosphate/Small Gold Nanorod Assemblies Using Poly(acrylic acid calcium salt) Nanospheres as Templates for Chemo-photothermal Combined Cancer Therapy. ACS Biomater. Sci. Eng. 2017, 3, 3215–3221. [Google Scholar] [CrossRef]
- Wu, Z.; Chen, J.; Sun, Y.; Zhao, D.; Shen, M.; Huang, L.; Xu, Q.; Duan, Y.; Li, Y. Tumor Microenvironment-Response Calcium Phosphate Hybrid Nanoparticles Enhanced siRNAs Targeting Tumors In Vivo. J. Biomed. Nanotechnol. 2018, 14, 1816–1825. [Google Scholar] [CrossRef]
- Bakshi, P.S.; Selvakumar, D.; Kadirvelu, K.; Kumar, N.S. Chitosan as an environment friendly biomaterial—A review on recent modifications and applications. Int. J. Biol. Macromol. 2020, 150, 1072–1083. [Google Scholar] [CrossRef]
- Negm, N.A.; Hefni, H.H.H.; Abd-Elaal, A.A.A.; Badr, E.A.; Abou Kana, M.T.H. Advancement on modification of chitosan biopolymer and its potential applications. Int. J. Biol. Macromol. 2020, 152, 681–702. [Google Scholar] [CrossRef]
- Shakil, M.S.; Mahmud, K.M.; Sayem, M.; Niloy, M.S.; Halder, S.K.; Hossen, M.S.; Uddin, M.F.; Hasan, M.A. Using Chitosan or Chitosan Derivatives in Cancer Therapy. Polysaccharides 2021, 2, 795–816. [Google Scholar] [CrossRef]
- Sharma, V.K.; Liu, X.; Oyarzún, D.A.; Abdel-Azeem, A.M.; Atanasov, A.G.; Hesham, A.E.-L.; Barik, S.K.; Gupta, V.K.; Singh, B.N. Microbial polysaccharides: An emerging family of natural biomaterials for cancer therapy and diagnostics. In Seminars in Cancer Biology; Academic Press: Cambridge, MA, USA, 2021. [Google Scholar] [CrossRef]
- Jiang, Z.; Han, B.; Li, H.; Yang, Y.; Liu, W. Carboxymethyl chitosan represses tumor angiogenesis in vitro and in vivo. Carbohydr. Polym. 2015, 129, 1–8. [Google Scholar] [CrossRef] [PubMed]
- Jiang, M.; Ouyang, H.; Ruan, P.; Zhao, H.; Pi, Z.; Huang, S.; Yi, P.; Crepin, M. Chitosan derivatives inhibit cell proliferation and induce apoptosis in breast cancer cells. Anticancer Res. 2011, 31, 1321–1328. [Google Scholar] [PubMed]
- Cui, Z.; Ni, N.C.; Wu, J.; Du, G.Q.; He, S.; Yau, T.M.; Weisel, R.D.; Sung, H.W.; Li, R.K. Polypyrrole-chitosan conductive biomaterial synchronizes cardiomyocyte contraction and improves myocardial electrical impulse propagation. Theranostics 2018, 8, 2752–2764. [Google Scholar] [CrossRef] [PubMed]
- Adhikari, H.S.; Yadav, P.N. Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action. Int. J. Biomater. 2018, 2018, 2952085. [Google Scholar] [CrossRef] [Green Version]
- Almeida, A.; Araújo, M.; Novoa-Carballal, R.; Andrade, F.; Gonçalves, H.; Reis, R.L.; Lúcio, M.; Schwartz, S.; Sarmento, B. Novel amphiphilic chitosan micelles as carriers for hydrophobic anticancer drugs. Mater. Sci. Eng. C 2020, 112, 110920. [Google Scholar] [CrossRef]
- Li, J.; Ying, S.; Ren, H.; Dai, J.; Zhang, L.; Liang, L.; Wang, Q.; Shen, Q.; Shen, J.W. Molecular dynamics study on the encapsulation and release of anti-cancer drug doxorubicin by chitosan. Int. J. Pharm. 2020, 580, 119241. [Google Scholar] [CrossRef]
- Wu, S.W.; Liu, X.; Miller, A.L.; Cheng, Y.S.; Yeh, M.L.; Lu, L. Strengthening injectable thermo-sensitive NIPAAm-g-chitosan hydrogels using chemical cross-linking of disulfide bonds as scaffolds for tissue engineering. Carbohydr. Polym. 2018, 192, 308–316. [Google Scholar] [CrossRef]
- Chen, Y.; Yan, X.; Zhao, J.; Feng, H.; Li, P.; Tong, Z.; Yang, Z.; Li, S.; Yang, J.; Jin, S. Preparation of the chitosan/poly(glutamic acid)/alginate polyelectrolyte complexing hydrogel and study on its drug releasing property. Carbohydr. Polym. 2018, 191, 8–16. [Google Scholar] [CrossRef]
- Rostami, E. Progresses in targeted drug delivery systems using chitosan nanoparticles in cancer therapy: A mini-review. J. Drug Deliv. Sci. Technol. 2020, 58, 101813. [Google Scholar] [CrossRef]
- Zhao, L.-M.; Shi, L.-E.; Zhang, Z.-L.; Chen, J.-M.; Shi, D.-D.; Yang, J.; Tang, Z.-X. Preparation and application of chitosan nanoparticles and nanofibers. Braz. J. Chem. Eng. 2011, 28, 353–362. [Google Scholar] [CrossRef]
- Szejtli, J. Introduction and General Overview of Cyclodextrin Chemistry. Chem. Rev. 1998, 98, 1743–1754. [Google Scholar] [CrossRef]
- Qiu, N.; Li, X.; Liu, J. Application of cyclodextrins in cancer treatment. J. Incl. Phenom. Macrocycl. Chem. 2017, 89, 229–246. [Google Scholar] [CrossRef]
- Szejtli, J.; Osa, T. Volume 3. Cyclodextrins. In Comprehensive Supramolecular Chemistry; Atwood, J.L., Lehn, J.M., Eds.; Pergamon: New York, NY, USA, 1996; ISBN 9780080406107. [Google Scholar]
- Gidwani, B.; Vyas, A. A Comprehensive Review on Cyclodextrin-Based Carriers for Delivery of Chemotherapeutic Cytotoxic Anticancer Drugs. Biomed Res. Int. 2015, 2015, 198268. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Loftsson, T.; Brewster, M.E. Pharmaceutical applications of cyclodextrins: Basic science and product development. J. Pharm. Pharmacol. 2010, 62, 1607–1621. [Google Scholar] [CrossRef] [PubMed]
- Tian, B.; Hua, S.; Liu, J. Cyclodextrin-based delivery systems for chemotherapeutic anticancer drugs: A review. Carbohydr. Polym. 2020, 232, 115805. [Google Scholar] [CrossRef] [PubMed]
- Arima, H.; Hagiwara, Y.; Hirayama, F.; Uekama, K. Enhancement of antitumor effect of doxorubicin by its complexation with γ-cyclodextrin in pegylated liposomes. J. Drug Target. 2006, 14, 225–232. [Google Scholar] [CrossRef] [PubMed]
- Balogh, L.P. (Ed.) Nanomedicine in Cancer; CRC Press: Boca Raton, FL, USA, 2017; ISBN 9781351627498. [Google Scholar]
- Cui, J.; Li, C.; Wang, C.; Li, Y.; Zhang, L.; Zhang, L.; Xiu, X.; Li, Y.; Wei, N. Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: Is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage? J. Pharm. Sci. 2011, 100, 2835–2848. [Google Scholar] [CrossRef]
- Qiu, N.; Cai, L.; Wang, W.; Wang, G.; Cheng, X.; Xu, Q.; Wen, J.; Liu, J.; Wei, Y.; Chen, L. Barbigerone-in-hydroxypropyl-β-cyclodextrin-liposomal nanoparticle: Preparation, characterization and anti-cancer activities. J. Incl. Phenom. Macrocycl. Chem. 2015, 82, 505–514. [Google Scholar] [CrossRef]
- Heidel, J.D.; Schluep, T. Cyclodextrin-Containing Polymers: Versatile Platforms of Drug Delivery Materials. J. Drug Deliv. 2012, 2012, 262731. [Google Scholar] [CrossRef] [Green Version]
- Swaminathan, S.; Cavalli, R.; Trotta, F. Cyclodextrin-based nanosponges: A versatile platform for cancer nanotherapeutics development. WIREs Nanomed. Nanobiotechnol. 2016, 8, 579–601. [Google Scholar] [CrossRef]
- Ishikawa, M.; Yoshii, H.; Furuta, T. Interaction of modified cyclodextrins with cytochrome P-450. Biosci. Biotechnol. Biochem. 2005, 69, 246–248. [Google Scholar] [CrossRef] [PubMed]
- Gooding, M.; Malhotra, M.; McCarthy, D.J.; Godinho, B.M.D.C.; Cryan, J.F.; Darcy, R.; O’Driscoll, C.M. Synthesis and characterization of rabies virus glycoprotein-tagged amphiphilic cyclodextrins for siRNA delivery in human glioblastoma cells: In vitro analysis. Eur. J. Pharm. Sci. 2015, 71, 80–92. [Google Scholar] [CrossRef] [PubMed]
- O’Mahony, A.M.; O’Neill, M.J.; Godinho, B.M.D.C.; Darcy, R.; Cryan, J.F.; O’Driscoll, C.M. Cyclodextrins for Non-Viral Gene and siRNA Delivery. Pharm. Nanotechnol. 2012, 1, 6–14. [Google Scholar] [CrossRef]
- O’Mahony, A.M.; Doyle, D.; Darcy, R.; Cryan, J.F.; O’Driscoll, C.M. Characterisation of cationic amphiphilic cyclodextrins for neuronal delivery of siRNA: Effect of reversing primary and secondary face modifications. Eur. J. Pharm. Sci. 2012, 47, 896–903. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mousazadeh, H.; Pilehvar-Soltanahmadi, Y.; Dadashpour, M.; Zarghami, N. Cyclodextrin based natural nanostructured carbohydrate polymers as effective non-viral siRNA delivery systems for cancer gene therapy. J. Control. Release 2021, 330, 1046–1070. [Google Scholar] [CrossRef]
- Caffall, K.H.; Mohnen, D. The structure, function, and biosynthesis of plant cell wall pectic polysaccharides. Carbohydr. Res. 2009, 344, 1879–1900. [Google Scholar] [CrossRef]
- Bergman, M.; Djaldetti, M.; Salman, H.; Bessler, H. Effect of citrus pectin on malignant cell proliferation. Biomed. Pharmacother. 2010, 64, 44–47. [Google Scholar] [CrossRef]
- Leclere, L.; Van Cutsem, P.; Michiels, C. Anti-cancer activities of pH- or heat-modified pectin. Front. Pharmacol. 2013, 4, 128. [Google Scholar] [CrossRef] [Green Version]
- Hao, M.; Yuan, X.; Cheng, H.; Xue, H.; Zhang, T.; Zhou, Y.; Tai, G. Comparative studies on the anti-tumor activities of high temperature- and pH-modified citrus pectins. Food Funct. 2013, 4, 960–971. [Google Scholar] [CrossRef]
- Khotimchenko, M. Pectin polymers for colon-targeted antitumor drug delivery. Int. J. Biol. Macromol. 2020, 158, 1110–1124. [Google Scholar] [CrossRef]
- Izadi, Z.; Divsalar, A.; Saboury, A.A.; Sawyer, L. β-lactoglobulin–pectin Nanoparticle-based Oral Drug Delivery System for Potential Treatment of Colon Cancer. Chem. Biol. Drug Des. 2016, 88, 209–216. [Google Scholar] [CrossRef] [PubMed]
- Zhang, W.; Mahuta, K.M.; Mikulski, B.A.; Harvestine, J.N.; Crouse, J.Z.; Lee, J.C.; Kaltchev, M.G.; Tritt, C.S. Novel pectin-based carriers for colonic drug delivery. Pharm. Dev. Technol. 2016, 21, 127–130. [Google Scholar] [CrossRef] [PubMed]
- Chambin, O.; Dupuis, G.; Champion, D.; Voilley, A.; Pourcelot, Y. Colon-specific drug delivery: Influence of solution reticulation properties upon pectin beads performance. Int. J. Pharm. 2006, 321, 86–93. [Google Scholar] [CrossRef] [PubMed]
- Wong, T.W.; Colombo, G.; Sonvico, F. Pectin Matrix as Oral Drug Delivery Vehicle for Colon Cancer Treatment. AAPS PharmSciTech 2011, 12, 201–214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Elyagoby, A.; Layas, N.; Wong, T.W. Colon-specific delivery of 5-fluorouracil from zinc pectinate pellets through In Situ intracapsular ethylcellulose-pectin plug formation. J. Pharm. Sci. 2013, 102, 604–616. [Google Scholar] [CrossRef]
- Zhang, L.; Cao, F.; Ding, B.; Li, Q.; Xi, Y.; Zhai, G. Eudragit® S100 coated calcium pectinate microspheres of curcumin for colon targeting. J. Microencapsul. 2011, 28, 659–667. [Google Scholar] [CrossRef]
- Lin, L.; Xu, W.; Liang, H.; He, L.; Liu, S.; Li, Y.; Li, B.; Chen, Y. Construction of pH-sensitive lysozyme/pectin nanogel for tumor methotrexate delivery. Colloids Surf. B Biointerfaces 2015, 126, 459–466. [Google Scholar] [CrossRef]
- Zhou, M.; Wang, T.; Hu, Q.; Luo, Y. Low density lipoprotein/pectin complex nanogels as potential oral delivery vehicles for curcumin. Food Hydrocoll. 2016, 57, 20–29. [Google Scholar] [CrossRef] [Green Version]
- Verma, A.K.; Kumar, A. Pharmacokinetics and biodistribution of negatively charged pectin nanoparticles encapsulating paclitaxel. Cancer Nanotechnol. 2013, 4, 99–102. [Google Scholar] [CrossRef] [Green Version]
- Liu, Y.; Kong, T.; Yang, Z.; Zhang, Y.; Lei, J.; Zhao, P. Self-Assembled Folic Acid-Targeted Pectin-Multi-Arm Polyethylene Glycol Nanoparticles for Tumor Intracellular Chemotherapy. ACS Omega 2021, 6, 1223–1234. [Google Scholar] [CrossRef]
- Byrne, J.D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 2008, 60, 1615–1626. [Google Scholar] [CrossRef] [PubMed]
- Shukla, A.A.; Thömmes, J. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol. 2010, 28, 253–261. [Google Scholar] [CrossRef] [PubMed]
- Sapsford, K.E.; Algar, W.R.; Berti, L.; Gemmill, K.B.; Casey, B.J.; Oh, E.; Stewart, M.H.; Medintz, I.L. Functionalizing Nanoparticles with Biological Molecules: Developing Chemistries that Facilitate Nanotechnology. Chem. Rev. 2013, 113, 1904–2074. [Google Scholar] [CrossRef]
- Wiseman, M.E.; Frank, C.W. Antibody adsorption and orientation on hydrophobic surfaces. Langmuir 2012, 28, 1765–1774. [Google Scholar] [CrossRef] [PubMed]
- Le Droumaguet, B.; Nicolas, J.; Brambilla, D.; Mura, S.; Maksimenko, A.; De Kimpe, L.; Salvati, E.; Zona, C.; Airoldi, C.; Canovi, M.; et al. Versatile and efficient targeting using a single nanoparticulate platform: Application to cancer and alzheimer’s disease. ACS Nano 2012, 6, 5866–5879. [Google Scholar] [CrossRef] [PubMed]
- Mamot, C.; Drummond, D.C.; Greiser, U.; Hong, K.; Kirpotin, D.B.; Marks, J.D.; Park, J.W.; Krishnada, A.; Onyuksel, H. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Women’s Oncol. Rev. 2004, 4, 101–103. [Google Scholar] [CrossRef]
- Karra, N.; Nassar, T.; Ripin, A.N.; Schwob, O.; Borlak, J.; Benita, S. Antibody conjugated PLGA nanoparticles for targeted delivery of paclitaxel palmitate: Efficacy and biofate in a lung cancer mouse model. Small 2013, 9, 4221–4236. [Google Scholar] [CrossRef]
- Eloy, J.O.; Ruiz, A.; de Lima, F.T.; Petrilli, R.; Raspantini, G.; Nogueira, K.A.B.; Santos, E.; de Oliveira, C.S.; Borges, J.C.; Marchetti, J.M.; et al. EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells. Colloids Surf. B Biointerfaces 2020, 194, 111185. [Google Scholar] [CrossRef]
- Chan, D.P.Y.; Deleavey, G.F.; Owen, S.C.; Damha, M.J.; Shoichet, M.S. Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery. Biomaterials 2013, 34, 8408–8415. [Google Scholar] [CrossRef]
- Kikumori, T.; Kobayashi, T.; Sawaki, M.; Imai, T. Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res. Treat. 2009, 113, 435–441. [Google Scholar] [CrossRef]
- Vorotnikov, Y.A.; Novikova, E.D.; Solovieva, A.O.; Shanshin, D.V.; Tsygankova, A.R.; Shcherbakov, D.N.; Efremova, O.A.; Shestopalov, M.A. Single-domain antibody C7b for address delivery of nanoparticles to HER2-positive cancers. Nanoscale 2020, 12, 21885–21894. [Google Scholar] [CrossRef] [PubMed]
- Ishida, T.; Kirchmeier, M.J.; Moase, E.H.; Zalipsky, S.; Allen, T.M. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta Biomembr. 2001, 1515, 144–158. [Google Scholar] [CrossRef] [Green Version]
- Harata, M.; Soda, Y.; Tani, K.; Ooi, J.; Takizawa, T.; Chen, M.; Bai, Y.; Izawa, K.; Kobayashi, S.; Tomonari, A.; et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood 2004, 104, 1442–1449. [Google Scholar] [CrossRef] [PubMed]
- Pan, H.; Li, S.; Li, M.; Tao, Q.; Jia, J.; Li, W.; Wang, L.; Guo, Z.; Ma, K.; Liu, Y.; et al. Anti-CD19 mAb-conjugated human serum albumin nanoparticles effectively deliver doxorubicin to B-lymphoblastic leukemia cells. Pharmazie 2020, 75, 318–323. [Google Scholar] [CrossRef]
- Li, S.; Goins, B.; Hrycushko, B.A.; Phillips, W.T.; Bao, A. Feasibility of eradication of breast cancer cells remaining in postlumpectomy cavity and draining lymph nodes following intracavitary injection of radioactive immunoliposomes. Mol. Pharm. 2012, 9, 2513–2522. [Google Scholar] [CrossRef] [Green Version]
- Hamaguchi, T.; Matsumura, Y.; Nakanishi, Y.; Muro, K.; Yamada, Y.; Shimada, Y.; Shirao, K.; Niki, H.; Hosokawa, S.; Tagawa, T.; et al. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci. 2004, 95, 608–613. [Google Scholar] [CrossRef]
- Li, F.; Lv, B.; Liu, Y.; Hua, T.; Han, J.; Sun, C.; Xu, L.; Zhang, Z.; Feng, Z.; Cai, Y.; et al. Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells. Oncoimmunology 2018, 7, e1391973. [Google Scholar] [CrossRef] [Green Version]
- Si, Y.; Zhang, Y.; Guan, J.-S.; Ngo, H.G.; Totoro, A.; Singh, A.P.; Chen, K.; Xu, Y.; Yang, E.S.; Zhou, L.; et al. Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers. Vaccines 2021, 9, 882. [Google Scholar] [CrossRef]
- Jayasena, S.D. Aptamers: An emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 1999, 45, 1628–1650. [Google Scholar] [CrossRef] [Green Version]
- Farokhzad, O.C.; Cheng, J.; Teply, B.A.; Sherifi, I.; Jon, S.; Kantoff, P.W.; Richie, J.P.; Langer, R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. USA 2006, 103, 6315–6320. [Google Scholar] [CrossRef] [Green Version]
- Zhou, G.; Latchoumanin, O.; Hebbard, L.; Duan, W.; Liddle, C.; George, J.; Qiao, L. Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. Adv. Drug Deliv. Rev. 2018, 134, 107–121. [Google Scholar] [CrossRef] [PubMed]
- Borghouts, C.; Kunz, C.; Groner, B. Peptide aptamers: Recent developments for cancer therapy. Expert Opin. Biol. Ther. 2005, 5, 783–797. [Google Scholar] [CrossRef] [PubMed]
- Baines, I.C.; Colas, P. Peptide aptamers as guides for small-molecule drug discovery. Drug Discov. Today 2006, 11, 334–341. [Google Scholar] [CrossRef] [PubMed]
- Qian, Z.M.; Tang, P.L. Mechanisms of iron uptake by mammalian cells. Biochim. Biophys. Acta Mol. Cell Res. 1995, 1269, 205–214. [Google Scholar] [CrossRef] [Green Version]
- Daniels, T.R.; Bernabeu, E.; Rodríguez, J.A.; Patel, S.; Kozman, M.; Chiappetta, D.A.; Holler, E.; Ljubimova, J.Y.; Helguera, G.; Penichet, M.L. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta Gen. Subj. 2012, 1820, 291–317. [Google Scholar] [CrossRef] [Green Version]
- Winkler, J.; Martin-Killias, P.; Plückthun, A.; Zangemeister-Wittke, U. EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins. Mol. Cancer Ther. 2009, 8, 2674–2683. [Google Scholar] [CrossRef] [Green Version]
- van den Brand, D.; van Lith, S.A.M.; de Jong, J.M.; Gorris, M.A.J.; Palacio-Castañeda, V.; Couwenbergh, S.T.; Goldman, M.R.G.; Ebisch, I.; Massuger, L.F.; Leenders, W.P.J.; et al. EpCAM-Binding DARPins for Targeted Photodynamic Therapy of Ovarian Cancer. Cancers 2020, 12, 1762. [Google Scholar] [CrossRef]
- Yu, D.-H.; Lu, Q.; Xie, J.; Fang, C.; Chen, H.-Z. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010, 31, 2278–2292. [Google Scholar] [CrossRef]
- Fu, X.; Lu, Y.; Guo, J.; Liu, H.; Deng, A.; Kuang, C.; Xie, X. K237-modified thermosensitive liposome enhanced the delivery efficiency and cytotoxicity of paclitaxel in vitro. J. Liposome Res. 2019, 29, 86–93. [Google Scholar] [CrossRef]
- Morelli, G.; Accardo, A.; Tesauro, D.; Cicala, C.; Salzano, G.; De Rosa, G.; Morisco, A.; Aloj, L.; Aurilio, M.; Maione, F.; et al. Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: A potential theranostic agent. Int. J. Nanomed. 2012, 7, 2007. [Google Scholar] [CrossRef] [Green Version]
- Radhakrishnan, R.; Pooja, D.; Kulhari, H.; Gudem, S.; Ravuri, H.G.; Bhargava, S.; Ramakrishna, S. Bombesin conjugated solid lipid nanoparticles for improved delivery of epigallocatechin gallate for breast cancer treatment. Chem. Phys. Lipids 2019, 224, 104770. [Google Scholar] [CrossRef] [PubMed]
- Iwase, Y.; Maitani, Y. Octreotide-Targeted Liposomes Loaded with CPT-11 Enhanced Cytotoxicity for the Treatment of Medullary Thyroid Carcinoma. Mol. Pharm. 2011, 8, 330–337. [Google Scholar] [CrossRef] [PubMed]
- Abdellatif, A.A.H.; Ibrahim, M.A.; Amin, M.A.; Maswadeh, H.; Alwehaibi, M.N.; Al-Harbi, S.N.; Alharbi, Z.A.; Mohammed, H.A.; Mehany, A.B.M.; Saleem, I. Cetuximab Conjugated with Octreotide and Entrapped Calcium Alginate-beads for Targeting Somatostatin Receptors. Sci. Rep. 2020, 10, 4736. [Google Scholar] [CrossRef] [PubMed]
- Daniels, T.R.; Delgado, T.; Rodriguez, J.A.; Helguera, G.; Penichet, M.L. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 2006, 121, 144–158. [Google Scholar] [CrossRef] [PubMed]
- Bazak, R.; Houri, M.; El Achy, S.; Kamel, S.; Refaat, T. Cancer active targeting by nanoparticles: A comprehensive review of literature. J. Cancer Res. Clin. Oncol. 2015, 141, 769–784. [Google Scholar] [CrossRef] [Green Version]
- Talekar, M.; Kendall, J.; Denny, W.; Garg, S. Targeting of nanoparticles in cancer. Anti-Cancer Drugs 2011, 22, 949–962. [Google Scholar] [CrossRef]
- Hilgenbrink, A.R.; Low, P.S. Folate Receptor-Mediated Drug Targeting: From Therapeutics to Diagnostics. J. Pharm. Sci. 2005, 94, 2135–2146. [Google Scholar] [CrossRef]
- Matherly, L.H.; Goldman, D.I. Membrane transport of folates. Vitam. Horm. 2003, 66, 403–456. [Google Scholar] [CrossRef]
- Yu, B.; Tai, H.C.; Xue, W.; Lee, L.J.; Lee, R.J. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol. Membr. Biol. 2010, 27, 286–298. [Google Scholar] [CrossRef] [Green Version]
- Zwicke, G.L.; Ali Mansoori, G.; Jeffery, C.J. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012, 3, 18496. [Google Scholar] [CrossRef]
- Lee, R.J.; Lee, R.J.; Zhang, M.; Yung, B.; Li, H.; Zhou, C.; Lee, L. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma. Int. J. Nanomed. 2012, 7, 5465. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seymour, L.W.; Ferry, D.R.; Anderson, D.; Hesslewood, S.; Julyan, P.J.; Poyner, R.; Doran, J.; Young, A.M.; Burtles, S.; Kerr, D.J. Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin. J. Clin. Oncol. 2002, 20, 1668–1676. [Google Scholar] [CrossRef] [PubMed]
- Suo, A.; Qian, J.; Yao, Y.; Zhang, W. Galactosylated poly(ethylene glycol)-b-poly (l-lactide-co-β-malic acid) block copolymer micelles for targeted drug delivery: Preparation and in vitro characterization. Int. J. Nanomed. 2010, 5, 1029–1038. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, Z.; Wu, P.; He, Z.; He, H.; Rong, W.; Li, J.; Zhou, D.; Huang, Y. Mesoporous silica nanoparticles with lactose-mediated targeting effect to deliver platinum(IV) prodrug for liver cancer therapy. J. Mater. Chem. B 2017, 5, 7591–7597. [Google Scholar] [CrossRef]
- Yang, L.; Xiao, H.; Yan, L.; Wang, R.; Huang, Y.; Xie, Z.; Jing, X. Lactose targeting oxaliplatin prodrug loaded micelles for more effective chemotherapy of hepatocellular carcinoma. J. Mater. Chem. B 2014, 2, 2097. [Google Scholar] [CrossRef]
- Thomas, G.E.; Szücs, M.; Mamone, J.Y.; Bem, W.T.; Rush, M.D.; Johnson, F.E.; Coscia, C.J. Sigma and opioid receptors in human brain tumors. Life Sci. 1990, 46, 1279–1286. [Google Scholar] [CrossRef]
- Johnson, F.E.; Thomas, G.E.; Mamone, J.Y.; Homan, S.M.; Levy, B.K.; Johnson, F.E.; Coscia, C.J. Overexpression of σ Receptors in Nonneural Human Tumors. Cancer Res. 1991, 51, 6558–6562. [Google Scholar]
- Vilner, B.J.; John, C.S.; Bowen, W.D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995, 55, 408–413. [Google Scholar]
- Crawford, K.W.; Bowen, W.D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002, 62, 313–322. [Google Scholar]
- Nakagawa, O.; Ming, X.; Huang, L.; Juliano, R.L. Targeted Intracellular Delivery of Antisense Oligonucleotides via Conjugation with Small-Molecule Ligands. J. Am. Chem. Soc. 2010, 132, 8848–8849. [Google Scholar] [CrossRef] [Green Version]
- Ramzy, L.; Nasr, M.; Metwally, A.A.; Awad, G.A.S. Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors. Eur. J. Pharm. Sci. 2017, 104, 273–292. [Google Scholar] [CrossRef] [PubMed]
- Srinivasarao, M.; Galliford, C.V.; Low, P.S. Principles in the design of ligand-targeted cancer therapeutics and imaging agents. Nat. Rev. Drug Discov. 2015, 14, 203–219. [Google Scholar] [CrossRef] [PubMed]
- Zhuang, C.; Guan, X.; Ma, H.; Cong, H.; Zhang, W.; Miao, Z. Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment. Eur. J. Med. Chem. 2019, 163, 883–895. [Google Scholar] [CrossRef] [PubMed]
- Leamon, C.P.; You, F.; Santhapuram, H.K.; Fan, M.; Vlahov, I.R. Properties Influencing the Relative Binding Affinity of Pteroate Derivatives and Drug Conjugates Thereof to the Folate Receptor. Pharm. Res. 2009, 26, 1315–1323. [Google Scholar] [CrossRef] [PubMed]
- Cazzamalli, S.; Dal Corso, A.; Widmayer, F.; Neri, D. Chemically Defined Antibody–and Small Molecule–Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. J. Am. Chem. Soc. 2018, 140, 1617–1621. [Google Scholar] [CrossRef] [Green Version]
- Chari, R.V.J.; Miller, M.L.; Widdison, W.C. Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy. Angew. Chem. Int. Ed. 2014, 53, 3796–3827. [Google Scholar] [CrossRef]
- Wang, D.; Peng, Y.; Deng, Z.; Tan, Y.; Su, Y.; Kuai, H.; Ai, L.; Huang, Z.; Wang, X.; Zhang, X.; et al. Modularly Engineered Solid-Phase Synthesis of Aptamer-Functionalized Small Molecule Drugs for Targeted Cancer Therapy. Adv. Ther. 2020, 3, 2000074. [Google Scholar] [CrossRef]
- Corti, A.; Pastorino, F.; Curnis, F.; Arap, W.; Ponzoni, M.; Pasqualini, R. Targeted Drug Delivery and Penetration Into Solid Tumors. Med. Res. Rev. 2012, 32, 1078–1091. [Google Scholar] [CrossRef]
- Cazzamalli, S.; Ziffels, B.; Widmayer, F.; Murer, P.; Pellegrini, G.; Pretto, F.; Wulhfard, S.; Neri, D. Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2. Clin. Cancer Res. 2018, 24, 3656–3667. [Google Scholar] [CrossRef] [Green Version]
- Liu, Y.; Dai, Z.; Wang, J.; Tu, Y.; Zhu, L. Folate-targeted pH-sensitive bortezomib conjugates for cancer treatment. Chem. Commun. 2019, 55, 4254–4257. [Google Scholar] [CrossRef]
- Chen, Y.-Y.; Lo, C.-F.; Chiu, T.-Y.; Hsu, C.-Y.; Yeh, T.-K.; Chen, C.-P.; Huang, C.-L.; Huang, C.-Y.; Wang, M.-H.; Huang, Y.-C.; et al. BPRDP056, a novel small molecule drug conjugate specifically targeting phosphatidylserine for cancer therapy. Transl. Oncol. 2021, 14, 100897. [Google Scholar] [CrossRef] [PubMed]
- Lee, S.; Lee, Y.; Kim, H.; Lee, D.Y.; Jon, S. Bilirubin Nanoparticle-Assisted Delivery of a Small Molecule-Drug Conjugate for Targeted Cancer Therapy. Biomacromolecules 2018, 19, 2270–2277. [Google Scholar] [CrossRef]
- Patel, T.K.; Adhikari, N.; Amin, S.A.; Biswas, S.; Jha, T.; Ghosh, B. Small molecule drug conjugates (SMDCs): An emerging strategy for anticancer drug design and discovery. New J. Chem. 2021, 45, 5291–5321. [Google Scholar] [CrossRef]
- Kruspe, S.; Giangrande, P. Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects. Biomedicines 2017, 5, 45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Turanov, A.A.; Lo, A.; Hassler, M.R.; Makris, A.; Ashar-Patel, A.; Alterman, J.F.; Coles, A.H.; Haraszti, R.A.; Roux, L.; Godinho, B.M.D.C.; et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 2018, 36, 1164–1173. [Google Scholar] [CrossRef] [PubMed]
- Watts, J.; Deleavey, G.; Damha, M. Chemically modified siRNA: Tools and applications. Drug Discov. Today 2008, 13, 842–855. [Google Scholar] [CrossRef]
- Dong, Y.; Siegwart, D.J.; Anderson, D.G. Strategies, design, and chemistry in siRNA delivery systems. Adv. Drug Deliv. Rev. 2019, 144, 133–147. [Google Scholar] [CrossRef]
- Ganta, S.; Devalapally, H.; Shahiwala, A.; Amiji, M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release 2008, 126, 187–204. [Google Scholar] [CrossRef]
- Alavizadeh, S.H.; Soltani, F.; Ramezani, M. Recent Advances in Immunoliposome-Based Cancer Therapy. Curr. Pharmacol. Rep. 2016, 2, 129–141. [Google Scholar] [CrossRef] [Green Version]
- Vingerhoeds, M.H.; Haisma, H.J.; van Muijen, M.; van de Rijt, R.B.J.; Crommelin, D.J.A.; Storm, G. A new application for liposomes in cancer therapy. Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of prodrugs. FEBS Lett. 1993, 336, 485–490. [Google Scholar] [CrossRef] [Green Version]
- de la Rica, R.; Aili, D.; Stevens, M.M. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv. Drug Deliv. Rev. 2012, 64, 967–978. [Google Scholar] [CrossRef] [PubMed]
- Zhu, L.; Kate, P.; Torchilin, V.P. Matrix Metalloprotease 2-Responsive Multifunctional Liposomal Nanocarrier for Enhanced Tumor Targeting. ACS Nano 2012, 6, 3491–3498. [Google Scholar] [CrossRef] [PubMed]
- Andresen, T.L.; Davidsen, J.; Begtrup, M.; Mouritsen, O.G.; Jørgensen, K. Enzymatic Release of Antitumor Ether Lipids by Specific Phospholipase A 2 Activation of Liposome-Forming Prodrugs. J. Med. Chem. 2004, 47, 1694–1703. [Google Scholar] [CrossRef] [PubMed]
- Ferguson, E.L.; Duncan, R. Dextrin−Phospholipase A 2: Synthesis and Evaluation as a Bioresponsive Anticancer Conjugate. Biomacromolecules 2009, 10, 1358–1364. [Google Scholar] [CrossRef] [PubMed]
- Napoli, A.; Boerakker, M.J.; Tirelli, N.; Nolte, R.J.M.; Sommerdijk, N.A.J.M.; Hubbell, J.A. Letters Glucose-oxidase Based Self-Destructing Polymeric Vesicles. ACS Publ. 2004, 20, 3487–3491. [Google Scholar] [CrossRef]
- Basel, M.T.; Shrestha, T.B.; Troyer, D.L.; Bossmann, S.H. Protease-Sensitive, Polymer-Caged Liposomes: A Method for Making Highly Targeted Liposomes Using Triggered Release. ACS Nano 2011, 5, 2162–2175. [Google Scholar] [CrossRef] [PubMed]
- Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 1989, 49, 6449–6465. [Google Scholar]
- Gerweck, L.E.; Seetharaman, K. Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Res. 1996, 56, 1194–1198. [Google Scholar]
- Wang, Y.; Liu, Y.; Liu, Y.; Wang, Y.; Wu, J.; Li, R.; Yang, J.; Zhang, N. pH-sensitive pullulan-based nanoparticles for intracellular drug delivery. Polym. Chem. 2014, 5, 423–432. [Google Scholar] [CrossRef]
- Jiang, H.-L.; Xing, L.; Zhou, T.-J.; Gong, J.-H.; He, Y.-J.; Zhuang, W.-R.; Cho, K.; Cho, C.-S. pH-Sensitive Modification of Chitosan as a Gene Carrier among Marine Biomaterials. In Encyclopedia of Marine Biotechnology; Wiley: Hoboken, NJ, USA, 2020; pp. 1249–1282. [Google Scholar]
- Mane, S.R. Advances of hydrazone linker in polymeric drug delivery. J. Crit. Rev. 2019, 6, 1–4. [Google Scholar] [CrossRef]
- Liu, C.G.; Kankala, R.K.; Liao, H.Y.; Chen, A.Z.; Wang, S. Bin Engineered pH-responsive hydrazone-carboxylate complexes-encapsulated 2D matrices for cathepsin-mediated apoptosis in cancer. J. Biomed. Mater. Res. Part A 2019, 107, 1184–1194. [Google Scholar] [CrossRef] [PubMed]
- Liu, B.; Chen, H.; Li, X.; Zhao, C.; Liu, Y.; Zhu, L.; Deng, H.; Li, J.; Li, G.; Guo, F.; et al. PH-responsive flower-like micelles constructed via oxime linkage for anticancer drug delivery. RSC Adv. 2014, 4, 48943–48951. [Google Scholar] [CrossRef]
- Hsu, C.W.; Hsieh, M.H.; Xiao, M.C.; Chou, Y.H.; Wang, T.H.; Chiang, W.H. pH-responsive polymeric micelles self-assembled from benzoic-imine-containing alkyl-modified PEGylated chitosan for delivery of amphiphilic drugs. Int. J. Biol. Macromol. 2020, 163, 1106–1116. [Google Scholar] [CrossRef] [PubMed]
- Hu, X.; Jazani, A.M.; Oh, J.K. Recent advances in development of imine-based acid-degradable polymeric nanoassemblies for intracellular drug delivery. Polymer 2021, 230, 124024. [Google Scholar] [CrossRef]
- Zhou, S.; Fu, S.; Wang, H.; Deng, Y.; Zhou, X.; Sun, W.; Zhai, Y. Acetal-linked polymeric prodrug micelles based on aliphatic polycarbonates for paclitaxel delivery: Preparation, characterization, in vitro release and anti-proliferation effects. J. Biomater. Sci. Polym. Ed. 2020, 31, 2007–2023. [Google Scholar] [CrossRef]
- Zhang, Y.; Lu, Y.; Cao, M.; Chen, P.; Yang, B.; Miao, J.; Xia, R.; Qian, J. Y-shaped copolymers of poly(ethylene glycol)-poly(ε-caprolactone) with ketal bond as the branchpoint for drug delivery. Mater. Sci. Eng. C 2018, 93, 554–564. [Google Scholar] [CrossRef]
- Gao, J.; Qiao, Z.; Liu, S.; Xu, J.; Wang, S.; Yang, X.; Wang, X.; Tang, R. A small molecule nanodrug consisting of pH-sensitive ortho ester–dasatinib conjugate for cancer therapy. Eur. J. Pharm. Biopharm. 2021, 163, 188–197. [Google Scholar] [CrossRef]
- Zhu, S.; Hong, M.; Tang, G.; Qian, L.; Lin, J.; Jiang, Y.; Pei, Y. Partly PEGylated polyamidoamine dendrimer for tumor-selective targeting of doxorubicin: The effects of PEGylation degree and drug conjugation style. Biomaterials 2010, 31, 1360–1371. [Google Scholar] [CrossRef]
- Palazzi, M.; Maluta, S.; Dall’Oglio, S.; Romano, M. The role of hyperthermia in the battle against cancer. Tumori J. 2010, 96, 902–910. [Google Scholar] [CrossRef]
- Meyer, D.; Shin, B.; Kong, G.; Dewhirst, M.W.; Chilkoti, A. Drug targeting using thermally responsive polymers and local hyperthermia. J. Control. Release 2001, 74, 213–224. [Google Scholar] [CrossRef]
- Kono, K. Thermosensitive polymer-modified liposomes. Adv. Drug Deliv. Rev. 2001, 53, 307–319. [Google Scholar] [CrossRef]
- Jeong, B.; Kim, S.W.; Bae, Y.H. Thermosensitive sol–gel reversible hydrogels. Adv. Drug Deliv. Rev. 2012, 64, 154–162. [Google Scholar] [CrossRef]
- Ito, A.; Kuga, Y.; Honda, H.; Kikkawa, H.; Horiuchi, A.; Watanabe, Y.; Kobayashi, T. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia. Cancer Lett. 2004, 212, 167–175. [Google Scholar] [CrossRef] [PubMed]
- Karimi, M.; Sahandi Zangabad, P.; Ghasemi, A.; Amiri, M.; Bahrami, M.; Malekzad, H.; Ghahramanzadeh Asl, H.; Mahdieh, Z.; Bozorgomid, M.; Ghasemi, A.; et al. Temperature-Responsive Smart Nanocarriers for Delivery Of Therapeutic Agents: Applications and Recent Advances. ACS Appl. Mater. Interfaces 2016, 8, 21107–21133. [Google Scholar] [CrossRef] [Green Version]
- Zhao, W.; Karp, J.M. Nanoantennas heat up. Nat. Mater. 2009, 8, 453–454. [Google Scholar] [CrossRef]
- Wang, L.; Lin, X.; Wang, J.; Hu, Z.; Ji, Y.; Hou, S.; Zhao, Y.; Wu, X.; Chen, C. Novel Insights into Combating Cancer Chemotherapy Resistance Using a Plasmonic Nanocarrier: Enhancing Drug Sensitiveness and Accumulation Simultaneously with Localized Mild Photothermal Stimulus of Femtosecond Pulsed Laser. Adv. Funct. Mater. 2014, 24, 4229–4239. [Google Scholar] [CrossRef]
- Singh, A.; Vaishagya, K.; Verma, R.K.; Shukla, R. Temperature/pH-Triggered PNIPAM-Based Smart Nanogel System Loaded With Anastrozole Delivery for Application in Cancer Chemotherapy. AAPS PharmSciTech 2019, 20, 213. [Google Scholar] [CrossRef]
- Cheng, C.-C.; Liang, M.-C.; Liao, Z.-S.; Huang, J.-J.; Lee, D.-J. Self-Assembled Supramolecular Nanogels as a Safe and Effective Drug Delivery Vector for Cancer Therapy. Macromol. Biosci. 2017, 17, 1600370. [Google Scholar] [CrossRef]
- Wen, Y.; Oh, J.K. Intracellular delivery cellulose-based bionanogels with dual temperature/pH-response for cancer therapy. Colloids Surf. B Biointerfaces 2015, 133, 246–253. [Google Scholar] [CrossRef]
- Banihashem, S.; Nezhati, M.N.; Panahia, H.A. Synthesis of chitosan-grafted-poly(N-vinylcaprolactam) coated on the thiolated gold nanoparticles surface for controlled release of cisplatin. Carbohydr. Polym. 2020, 227, 115333. [Google Scholar] [CrossRef]
- Meng, F.; Hennink, W.E.; Zhong, Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials 2009, 30, 2180–2198. [Google Scholar] [CrossRef] [PubMed]
- Wu, G.; Fang, Y.-Z.; Yang, S.; Lupton, J.R.; Turner, N.D. Glutathione Metabolism and Its Implications for Health. J. Nutr. 2004, 134, 489–492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aon, M.; Cortassa, S.; O’Rourke, B. Redox-optimized ROS balance: A unifying hypothesis. Biochim. Biophys. Acta Bioenerg. 2010, 1797, 865–877. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Huo, M.; Yuan, J.; Tao, L.; Wei, Y. Redox-responsive polymers for drug delivery: From molecular design to applications. Polym. Chem. 2014, 5, 1519–1528. [Google Scholar] [CrossRef]
- McCarley, R.L. Redox-Responsive Delivery Systems. Annu. Rev. Anal. Chem. 2012, 5, 391–411. [Google Scholar] [CrossRef]
- Sauraj; Kumar, V.; Kumar, B.; Priyadarshi, R.; Deeba, F.; Kulshreshtha, A.; Kumar, A.; Agrawal, G.; Gopinath, P.; Negi, Y.S. Redox responsive xylan-SS-curcumin prodrug nanoparticles for dual drug delivery in cancer therapy. Mater. Sci. Eng. C 2020, 107, 110356. [Google Scholar] [CrossRef]
- Liang, Y.; Kiick, K.L. Liposome-Cross-Linked Hybrid Hydrogels for Glutathione-Triggered Delivery of Multiple Cargo Molecules. Biomacromolecules 2016, 17, 601–614. [Google Scholar] [CrossRef] [Green Version]
- Mirhadi, E.; Mashreghi, M.; Faal Maleki, M.; Alavizadeh, S.H.; Arabi, L.; Badiee, A.; Jaafari, M.R. Redox-sensitive nanoscale drug delivery systems for cancer treatment. Int. J. Pharm. 2020, 589, 119882. [Google Scholar] [CrossRef]
- Senthil, K.; Aranganathan, S.; Nalini, N. Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin. Chim. Acta 2004, 339, 27–32. [Google Scholar] [CrossRef]
- Saravanakumar, G.; Kim, J.; Kim, W.J. Reactive-Oxygen-Species-Responsive Drug Delivery Systems: Promises and Challenges. Adv. Sci. 2017, 4, 1600124. [Google Scholar] [CrossRef]
- Zhang, Z.; Wang, R.; Huang, X.; Luo, R.; Xue, J.; Gao, J.; Liu, W.; Liu, F.; Feng, F.; Qu, W. Self-Delivered and Self-Monitored Chemo-Photodynamic Nanoparticles with Light-Triggered Synergistic Antitumor Therapies by Downregulation of HIF-1α and Depletion of GSH. ACS Appl. Mater. Interfaces 2020, 12, 5680–5694. [Google Scholar] [CrossRef] [PubMed]
- Cheng, Y.; Jiao, X.; Xu, T.; Wang, W.; Cao, Y.; Wen, Y.; Zhang, X. Free-Blockage Mesoporous Anticancer Nanoparticles Based on ROS-Responsive Wetting Behavior of Nanopores. Small 2017, 13, 1701942. [Google Scholar] [CrossRef] [PubMed]
- Zheng, N.; Xie, D.; Zhang, Z.; Kuang, J.; Zheng, Y.; Wang, Q.; Li, Y. Thioketal-crosslinked: ROS-degradable polycations for enhanced in vitro and in vivo gene delivery with self-diminished cytotoxicity. J. Biomater. Appl. 2019, 34, 326–338. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.G.; Robby, A.I.; Lee, B.C.; Lee, G.; Park, S.Y. Mitochondria-targeted ROS- and GSH-responsive diselenide-crosslinked polymer dots for programmable paclitaxel release. J. Ind. Eng. Chem. 2021, 99, 98–106. [Google Scholar] [CrossRef]
- Wang, Y.; Deng, Y.; Luo, H.; Zhu, A.; Ke, H.; Yang, H.; Chen, H. Light-Responsive Nanoparticles for Highly Efficient Cytoplasmic Delivery of Anticancer Agents. ACS Nano 2017, 11, 12134–12144. [Google Scholar] [CrossRef]
- Liu, C.; Zhang, Y.; Liu, M.; Chen, Z.; Lin, Y.; Li, W.; Cao, F.; Liu, Z.; Ren, J.; Qu, X. A NIR-controlled cage mimicking system for hydrophobic drug mediated cancer therapy. Biomaterials 2017, 139, 151–162. [Google Scholar] [CrossRef]
- Tao, W.; He, Z. ROS-responsive drug delivery systems for biomedical applications. Asian J. Pharm. Sci. 2018, 13, 101–112. [Google Scholar] [CrossRef]
- Ma, N.; Li, Y.; Xu, H.; Wang, Z.; Zhang, X. Dual redox responsive assemblies formed from diselenide block copolymers. J. Am. Chem. Soc. 2010, 132, 442–443. [Google Scholar] [CrossRef]
- Chiang, Y.-T.; Yen, Y.-W.; Lo, C.-L. Reactive oxygen species and glutathione dual redox-responsive micelles for selective cytotoxicity of cancer. Biomaterials 2015, 61, 150–161. [Google Scholar] [CrossRef]
- Luo, C.Q.; Zhou, Y.X.; Zhou, T.J.; Xing, L.; Cui, P.F.; Sun, M.; Jin, L.; Lu, N.; Jiang, H.L. Reactive oxygen species-responsive nanoprodrug with quinone methides-mediated GSH depletion for improved chlorambucil breast cancers therapy. J. Control. Release 2018, 274, 56–68. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Veselov, V.V.; Nosyrev, A.E.; Jicsinszky, L.; Alyautdin, R.N.; Cravotto, G. Targeted Delivery Methods for Anticancer Drugs. Cancers 2022, 14, 622. https://doi.org/10.3390/cancers14030622
Veselov VV, Nosyrev AE, Jicsinszky L, Alyautdin RN, Cravotto G. Targeted Delivery Methods for Anticancer Drugs. Cancers. 2022; 14(3):622. https://doi.org/10.3390/cancers14030622
Chicago/Turabian StyleVeselov, Valery V., Alexander E. Nosyrev, László Jicsinszky, Renad N. Alyautdin, and Giancarlo Cravotto. 2022. "Targeted Delivery Methods for Anticancer Drugs" Cancers 14, no. 3: 622. https://doi.org/10.3390/cancers14030622